AZN Astrazeneca PLC

48.57
+0.65  (+1%)
Previous Close 47.92
Open 48.38
Price To Book 9.41
Market Cap 127,439,254,854
Shares 2,623,826,536
Volume 304,198
Short Ratio 2.33
Av. Daily Volume 3,072,389
Stock charts supplied by TradingView

NewsSee all news

  1. Moderna Announces Key 2020 Investor and Analyst Events

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its key

  2. [Fam]-Trastuzumab Deruxtecan Achieved a Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Trial

    AstraZeneca and Daiichi Sankyo's [fam]-trastuzumab deruxtecan demonstrated an impressive 14.8-month median duration of response and 16.4-month median progression-free survival AstraZeneca and Daiichi Sankyo Company,

  3. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  4. CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia

    Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24

  5. CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia

    Two Phase III CALQUENCE trials demonstrated superior progression-free survival across multiple settings while maintaining favorable tolerability CALQUENCE combined with obinutuzumab and as monotherapy reduced the risk

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 poster at ESMO September 28, 2019.
Tagrisso and Lerociclib (G1T38)
EGFR mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due late-2020.
Tezepelumab - NAVIGATOR
Asthma
Expanded approval announced August 28, 2017.
Faslodex (fulvestrant)
Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer
NDA filing due 4Q 2019.
Roxadustat
Anaemia in Chronic Kidney Disease
Phase 3 data due 2021.
Farxiga (Dapa-CKD)
Chronic Kidney Disease
FDA Approval announced October 21, 2019.
Farxiga - DECLARE
Heart failure in patients with type-2 diabetes
Phase 2 trial to be completed in 2020.
MEDI0457
HPV-associated squamous cell carcinoma of the head & neck (SCCHN)
Phase 3 data released November 1, 2017 - primary endpoint not met.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
Phase 3 data met primary endpoint - August 20, 2019. Noted at ESC Congress 2019 that cardiovascular death/worsening of heart failure was reduced by 26%.
Farxiga (Dapa-HF)
Heart failure
Phase 3 data released May 30, 2018. Primary endpoint not met.
Benralizumab - TERRANOVA
COPD
Phase 3 data due 2H 2020.
Roxadustat
Myelodysplastic syndromes (MDS)
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2021.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 trial did not meet primary endpoint - noted July 26, 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data released August 28, 2019. Primary endpoint met.
Breztri - (ETHOS)
Chronic obstructive pulmonary disease (COPD)
FDA approval announced September 13, 2018.
Moxetumomab
Cancer - leukaemia
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Approval announced August 17, 2017.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 data released July 27, 2017 - primary endpoint (PFS) not met. Overall survival data also did not meet primary endpoint - November 16, 2018.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data released August 21, 2019 did not meet primary endpoint.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data 1H 2020.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 1H 2020.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data released December 7, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data released April 24, 2018 - primary endpoints not met.
Durvalumab +/- tremelimumab (ARCTIC)
Non-small cell lung cancer (NSCLC)
Approval announced February 19, 2018.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).
Bydureon
Type 2 Diabetes
Phase 3 data released February 25, 2019 met primary endpoint. Data presented at ESC Congress September 1, 2019 noted the treatment exhibited a reduction of cardiovascular (CV) death, heart attack, or stroke by 10% .
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met. TULIP 2 data released August 29, 2019 did meet primary endpoint.
Anifrolumab
Lupus
Priority Review announced August 2, 2017. Approval announced October 31, 2017.
Acalabrutinib
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017. Approval announced May 18, 2018.
Lokelma (ZS-9)
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Approval announced November 14, 2017.
Benralizumab
Severe, uncontrolled asthma
Announced discontinuation of trial due to futility - June 12, 2018.
Lanabecestat (AZD3293) - AMARANTH
Early Alzheimer's disease
Phase 3 data met primary and secondary endpoints. ORR; 72.2% vs 51.4% for chemotherapy. PFS 13.4 months vs 9.2 months for chemo arm (HR 0.62).
Lynparza - SOLO 3
Third-line ovarian cancer
Phase 3 data at ASCO noted median PFS 7.4 months vs 3.8 months for placebo. HR 0.53.
Lynparza (POLO)
Pancreatic cancer
Phase 3 PFS data met primary endpoint. OS data due 2020.
Imfinzi + tremelimumab (POSEIDON)
Non-small cell lung cancer (NSCLC)
PDUFA date under priority review announced November 29, 2019. No PDUFA date announced. Estimate March 29, 2019.
Imfinzi + tremelimumab (CASPIAN)
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
Phase 3 trial did not meet primary endpoint - noted May 11, 2018.
Fasenra (benralizumab) - GALATHEA
Chronic obstructive pulmonary disease (COPD)
Phase 3 trial met primary endpoint. Presentation at ESMO 2019 noted PFS 7.4 months vs. 3.6 months - standard of care.
Lynparza
Castration-Resistant Prostate Cancer
FDA Approval announced November 21, 2019.
Calquence
Chronic lymphocytic leukaemia
Phase 3 data met primary endpoint - August 14, 2019. Presentation at ESMO noted PFS HR 0.59.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 1b/2 data likely due 2020.
Durvalumab Plus Danvatirsen
Refractory head and neck cancer
Phase 3 final OS data released August 9, 2019. Endpoint met. Presentation at ESMO September 2019 noted OS of 38.6 months versus 31.8 months for comparator arm; PFS HR 0.48.
Tagrisso - FLAURA
Non-small cell lung cancer (NSCLC)
Phase 3 data due 1H 2020.
Brilinta (THALES)
Acute ischaemic stroke
Phase 3 data due 2H 2020.
Epanova
Hypertriglyceridaemia CVOT
Phase 3 data due 2H 2020.
Fasenra
Nasal polyps
Phase 3 data due 2H 2020.
Imfinzi
Neoadjuvant Non-small cell lung cancer (NSCLC)
Phase 2 trial met primary endpoint - noted April 4, 2019.
Fasenra
Hypereosinophilic Syndrome
Phase 3 data due 2021.
Trastuzumab deruxtecan - DESTINY-Breast04
HER low breast cancer
Phase 3 data due 2021.
Trastuzumab deruxtecan - DESTINY-Breast03
Second line HER2+ breast cancer
Phase 3 data due 2021.
Trastuzumab deruxtecan DESTINY-Breast02
Third line HER2+ breast cancer
PDUFA date under priority review announced October 17, 2019. PDUFA date not announced. Estimate April 17, 2019 using 6-mth timeline.
Trastuzumab deruxtecan - - DESTINY-Breast01
Third line HER2+ breast cancer
Phase 3 data due 2020+.
Fasenra
Asthma
Phase 3 data due 2021+.
Farxiga (Deliver)
Chronic Heart Failure (CHF), preserved ejection fraction (HFpEF)
Phase 3 positive interim data released May 7, 2019. Trial to be stopped early.
Calquence
Relapsed/refractory chronic lymphocytic leukaemia
FDA approval announced May 3, 2019.
Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride)
Type 2 diabetes
CRL issued for sNDA announced July 15, 2019.
Farxiga (Depict)
Type 1 diabetes
Phase 3 data due 2H 2020.
PT027
Asthma
Phase 3 data due 2H 2020.
Imfinzi - PACIFIC2
Non-small cell lung cancer (NSCLC)
Phase 2 data due 1H 2020.
Trastuzumab deruxtecan - Gastric01
Gastric cancer
CRL announced October 1, 2019.
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 1H 2020.
Lynparza + cediranib
Ovarian cancer
Phase 3 data due 2021.
Imfinzi (PEARL)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2021.
Imfinzi (PACIFIC-5)
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2021.
Imfinzi + tremelimumab (NILE)
Bladder cancer
Phase 3 data due 2H 2020.
Imfinzi + tremelimumab - HIMALAYA
Hepatocellular carcinoma (HCC)
Phase 2 trial to commence 4Q 2019.
Efgartigimod (ARGX-113)
Chronic inflammatory demyelinating polyneuropathy

Latest News

  1. Moderna Announces Key 2020 Investor and Analyst Events

    Moderna, Inc., (NASDAQ:MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced its key

  2. [Fam]-Trastuzumab Deruxtecan Achieved a Tumor Response of 60.9% in Pivotal Phase II HER2-positive Metastatic Breast Cancer Trial

    AstraZeneca and Daiichi Sankyo's [fam]-trastuzumab deruxtecan demonstrated an impressive 14.8-month median duration of response and 16.4-month median progression-free survival AstraZeneca and Daiichi Sankyo Company,

  3. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  4. CALQUENCE Significantly Prolonged the Time Patients Lived Without Disease Progression or Death in Previously Untreated Chronic Lymphocytic Leukemia

    Full results from Phase III ELEVATE TN trial showed 93% of patients on CALQUENCE combined with obinutuzumab vs. 47% of patients on chlorambucil plus obinutuzumab remained free of disease progression or death at 24

  5. CALQUENCE Approved in the US for Adult Patients With Chronic Lymphocytic Leukemia

    Two Phase III CALQUENCE trials demonstrated superior progression-free survival across multiple settings while maintaining favorable tolerability CALQUENCE combined with obinutuzumab and as monotherapy reduced the risk

  6. Subgroup Analysis of TWILIGHT Trial Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Who Underwent PCI Showed BRILINTA Monotherapy Reduced the Risk of Clinically Relevant Bleeding Compared With Dual Antiplatelet Therapy (DAPT)

     Secondary endpoint of subgroup analysis showed similar rates of the composite of all-cause death, myocardial infarction or stroke between monotherapy and DAPT Results of subgroup analysis of TWILIGHT randomized

  7. Consistent Effects of FARXIGA in Heart Failure Patients With Reduced Ejection Fraction Shown in New Analyses From Landmark Phase III DAPA-HF Trial

    Data were consistent in patients with and without type 2 diabetes, showed early effects in the first month and improvement in patient-reported outcomes AstraZeneca today announced new data from five additional

  8. AstraZeneca Launches Diabetes Can Break Your Heart

     Announced on World Diabetes Day, the national movement will travel across America in 2020 to educate and activate communities around the connection between type 2 diabetes and heart failure AstraZeneca today announced

  9. Innate Pharma third quarter 2019 report

    Cash, cash equivalents and financial assets of the Company amounted to €215.2 millioni $79.1 million (€71.4 millionii) in gross proceeds from our IPO on the Nasdaq and Global Offering Monalizumab to advance to

  10. Aravive and AstraZeneca Announce Initiation of Randomized Phase 1/2 Study of AVB-500 in Combination with Durvalumab in Patients with Platinum-Resistant Recurrent Epithelial Ovarian Cancer

    HOUSTON and WILMINGTON, Del., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (NASDAQ:ARAV) and AstraZeneca (NYSE:AZN) today announced that an investigator-sponsored Phase 1/2 clinical trial of AVB-500, a GAS6/AXL

  11. Roxadustat Phase III Program Pooled Analyses Showed Positive Efficacy and No Increased Cardiovascular Risk in Patients with Anemia from Chronic Kidney Disease Versus Comparators

    In non dialysis-dependent patients receiving roxadustat, the risk of MACE, MACE+ and all-cause mortality was comparable to placebo Dialysis-dependent patients receiving roxadustat had a lower risk of MACE+ and no

  12. New Data From the Phase III DAPA-HF Trial Showed FARXIGA Reduced the Worsening of Heart Failure or Cardiovascular Death in HFrEF Patients With and Without Chronic Kidney Disease

    AstraZeneca today announced a pre-specified sub-analysis from the landmark Phase III DAPA-HF trial investigating FARXIGA® (dapagliflozin) for the treatment of heart failure (HF). The data showed that FARXIGA on top of

  13. Roxadustat Significantly Increased Hemoglobin Levels for Chronic Kidney Disease Patients with Anemia in Phase III OLYMPUS and ROCKIES Trials

    OLYMPUS demonstrated a mean increase of 1.75g/dL averaged over weeks 28 to 52, compared to 0.40g/dL with placebo ROCKIES demonstrated a mean increase of 0.77g/dL averaged over weeks 28 to 52, compared to 0.68g/dL with

  14. CALQUENCE® Data To Show Improved Progression-Free Survival In Phase III Front-Line Chronic Lymphocytic Leukemia At ASH 2019 Annual Meeting

    Robust early-stage pipeline advancements and presentations across multiple scientific platforms demonstrate potential to improve treatment outcomes in blood cancers with high unmet need AstraZeneca will present the

  15. Antengene Corporation Announces Exclusive Worldwide License to Develop and Commercialize AZD0364

    SHANGHAI and LONDON, Nov. 6, 2019 /PRNewswire/ -- Antengene Corporation today announced that it has entered into a licensing agreement with AstraZeneca (NYSE:AZN) under which Antengene has been granted the exclusive

  16. AstraZeneca to Present Pivotal Roxadustat Phase III Data at the American Society of Nephrology Kidney Week 2019

    Pooled efficacy and cardiovascular safety analyses from global Phase III program, and efficacy data from Phase III OLYMPUS and ROCKIES trials to be presented Unprecedented 41 abstracts from the AstraZeneca renal

  17. IMFINZI® (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line Treatment of Stage IV Non-Small Cell Lung Cancer

    POSEIDON included both non-squamous and squamous patients and a broad choice of standard chemotherapy options AstraZeneca today announced positive progression-free survival (PFS) results for IMFINZI and tremelimumab,

  18. ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company's CD8 ImmunoPET technology

    LOS ANGELES, Oct. 14, 2019 /PRNewswire/ -- ImaginAb, Inc., a leading clinical-stage immuno-oncology imaging company, today announced the signing of a multi-party collaboration agreement with AstraZeneca (NYSE:AZN),

  19. AstraZeneca Launches Signature STEM Program to Empower Students to Live Healthier Lives and Inspire Future Scientists

    ‘Generation Health: How Science Powers Us' is a dynamic program designed to make the connection between students' health and the science behind the prevention and treatment of diseases AstraZeneca today announced the

  20. FASENRA® (benralizumab) Approved in the US for Self-administration in a New Pre-filled Auto-injector, the FASENRA Pen™

    FASENRA is now the only respiratory biologic that offers the choice of administration at home or in a doctor's office with eight-week maintenance dosing AstraZeneca today announced that the US Food and Drug

  21. Innate Pharma presents early clinical data on IPH5401 and monalizumab at the ESMO 2019 congress

    IPH5401 dose-escalation study in combination with durvalumab in advanced solid tumors, STELLAR-001, shows manageable safety profile Initiation of two expansion cohorts in non-small cell lung cancer (NSCLC) with

  22. LYNPARZA (olaparib) More Than Doubled the Time Without Radiographic Disease Progression in Patients With BRCA1/2- or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

    AstraZeneca and Merck's LYNPARZA reduced the risk of disease progression or death by 51% in men with homologous recombination repair (HRR) gene mutations First positive Phase III trial testing a targeted treatment in

  23. TAGRISSO Is the Only 1st-line Treatment for EGFR-Mutated Non-Small Cell Lung Cancer to Deliver a Median Overall Survival of More Than Three Years

    28% of patients in the global FLAURA trial were still receiving TAGRISSO at three years vs. 9% on either gefitinib or erlotinib TAGRISSO showed a 52% reduction in risk of central nervous system disease progression or

  24. LYNPARZA (olaparib) Improved the Time Women Lived Without Disease Progression to 22 Months in the Broad Population and 37 Months in HRD-positive Patients as 1st-line Maintenance Treatment with Bevacizumab for Newly Diagnosed Advanced Ovarian Cancer

    AstraZeneca and Merck's LYNPARZA added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as

  25. BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial

    Secondary endpoint of non-inferiority achieved for the risk of composite of MI, death or stroke Results presented at TCT 2019 conference and published in the New England Journal of Medicine New data from TWILIGHT, a

  26. Monalizumab to advance to Phase III in head and neck cancer

    Marseille, France, September 26, 2019, 7:00 AM CEST Innate Pharma SA (the "Company" or "Innate" - Euronext Paris: FR0010331421 – IPH), today announced that AstraZeneca (NYSE:AZN) will advance monalizumab into a Phase

  27. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NetworkNewsWire Editorial Coverage: Advances in biotechnology look to deliver promising new treatment options against breast cancer. Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX Profile)

  28. Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers

    NEW YORK, Sept. 24, 2019 /PRNewswire/ -- Advances in biotechnology look to deliver promising new treatment options against breast cancer.  Independent researchers have found that Genprex Inc.'s (NASDAQ:GNPX) (GNPX

  29. Biotech Companies Endeavor to Address Global Health Issues

    NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report

  30. FDA Grants Fast Track Designation for FARXIGA in Heart Failure

    AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the

  31. IMFINZI Is First Immunotherapy to Show Both Significant Survival Benefit and Improved, Durable Responses in Extensive-Stage Small Cell Lung Cancer

    In the Phase III CASPIAN trial IMFINZI at a fixed, convenient dose improved survival with either a cisplatin or carboplatin chemotherapy backbone AstraZeneca today presented detailed results from the Phase III CASPIAN

  32. Theragnostics Signs Agreement with AstraZeneca

    LONDON, Sept. 5, 2019 /PRNewswire/ -- Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, announces a licence agreement with AstraZeneca (NYSE:AZN) for

  33. BRILINTA Reduced the Risk of Cardiovascular Events in Patients With Coronary Artery Disease and Type 2 Diabetes in Phase III THEMIS Trial

    AstraZeneca today announced detailed results from the positive Phase III THEMIS trial, which showed BRILINTA (ticagrelor) plus aspirin reduced the relative risk for the composite of cardiovascular (CV) death, heart

  34. Detailed Results from Phase III DAPA-HF Trial Showed FARXIGA Significantly Reduced Both the Incidence of Cardiovascular Death and the Worsening of Heart Failure

    DAPA-HF is the first outcomes trial with an SGLT2 inhibitor in patients with heart failure with reduced ejection fraction, with and without type 2 diabetes AstraZeneca today announced detailed results from the landmark

  35. PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

    At both standard and low budesonide doses, the triple-combination therapy showed a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies First

  36. PT010 Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease

    At both standard and low budesonide doses, the triple-combination therapy showed a statistically-significant reduction in the rate of moderate or severe exacerbations compared with dual-combination therapies First

  37. FDA Grants Fast Track Designation for FARXIGA in Chronic Kidney Disease

    AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to delay the progression of renal failure and prevent